282 related articles for article (PubMed ID: 26758952)
1. Mevalonate Cascade and Small Rho GTPase in Spinal Cord Injury.
Eftekharpour E; Nagakannan P; Iqbal MA; Chen QM
Curr Mol Pharmacol; 2017; 10(2):141-151. PubMed ID: 26758952
[TBL] [Abstract][Full Text] [Related]
2. Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application.
Jiao X; Ashtari N; Rahimi-Balaei M; Chen QM; Badbezanchi I; Shojaei S; Marzban A; Mirzaei N; Chung S; Guan T; Li J; Vriend J; Mehr SE; Kong J; Marzban H
Curr Mol Pharmacol; 2017; 10(2):115-140. PubMed ID: 26758948
[TBL] [Abstract][Full Text] [Related]
3. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Yeganeh B; Wiechec E; Ande SR; Sharma P; Moghadam AR; Post M; Freed DH; Hashemi M; Shojaei S; Zeki AA; Ghavami S
Pharmacol Ther; 2014 Jul; 143(1):87-110. PubMed ID: 24582968
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury.
Kopp MA; Liebscher T; Niedeggen A; Laufer S; Brommer B; Jungehulsing GJ; Strittmatter SM; Dirnagl U; Schwab JM
Cell Tissue Res; 2012 Jul; 349(1):119-32. PubMed ID: 22350947
[TBL] [Abstract][Full Text] [Related]
5. Strategies to neutralize RhoA/ROCK pathway after spinal cord injury.
Roy A; Pathak Z; Kumar H
Exp Neurol; 2021 Sep; 343():113794. PubMed ID: 34166685
[TBL] [Abstract][Full Text] [Related]
6. Myelin Lipids Inhibit Axon Regeneration Following Spinal Cord Injury: a Novel Perspective for Therapy.
Mar FM; da Silva TF; Morgado MM; Rodrigues LG; Rodrigues D; Pereira MIL; Marques A; Sousa VF; Coentro J; Sá-Miranda C; Sousa MM; Brites P
Mol Neurobiol; 2016 Mar; 53(2):1052-1064. PubMed ID: 25579385
[TBL] [Abstract][Full Text] [Related]
7. Mevalonate Cascade and its Regulation in Cholesterol Metabolism in Different Tissues in Health and Disease.
Hashemi M; Hoshyar R; Ande SR; Chen QM; Solomon C; Zuse A; Naderi M
Curr Mol Pharmacol; 2017; 10(1):13-26. PubMed ID: 26758949
[TBL] [Abstract][Full Text] [Related]
8. Rho signaling pathway targeted to promote spinal cord repair.
Dergham P; Ellezam B; Essagian C; Avedissian H; Lubell WD; McKerracher L
J Neurosci; 2002 Aug; 22(15):6570-7. PubMed ID: 12151536
[TBL] [Abstract][Full Text] [Related]
9. Rho-ROCK inhibitors for the treatment of CNS injury.
Kubo T; Yamashita T
Recent Pat CNS Drug Discov; 2007 Nov; 2(3):173-9. PubMed ID: 18221230
[TBL] [Abstract][Full Text] [Related]
10. Combined application of Rho-ROCKII and GSK-3β inhibitors exerts an improved protective effect on axonal regeneration in rats with spinal cord injury.
Zhang G; Lei F; Zhou Q; Feng D; Bai Y
Mol Med Rep; 2016 Dec; 14(6):5180-5188. PubMed ID: 27840930
[TBL] [Abstract][Full Text] [Related]
11. Basic and Clinical Observations of Mevalonate Depletion on the Mevalonate Signaling Pathway.
Muller AL; Freed DH
Curr Mol Pharmacol; 2017; 10(1):6-12. PubMed ID: 26758946
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of intracellular Rho to stimulate axon growth and regeneration.
Ellezam B; Dubreuil C; Winton M; Loy L; Dergham P; Sellés-Navarro I; McKerracher L
Prog Brain Res; 2002; 137():371-80. PubMed ID: 12440379
[TBL] [Abstract][Full Text] [Related]
13. Rho-ROCK inhibition in the treatment of spinal cord injury.
Forgione N; Fehlings MG
World Neurosurg; 2014; 82(3-4):e535-9. PubMed ID: 23298675
[TBL] [Abstract][Full Text] [Related]
14. Lentivirus-mediated PGC-1α overexpression protects against traumatic spinal cord injury in rats.
Hu J; Lang Y; Zhang T; Ni S; Lu H
Neuroscience; 2016 Jul; 328():40-9. PubMed ID: 27132229
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin promotes neurite outgrowth in the presence of inhibitory molecules found in central nervous system injury.
Holmberg E; Nordstrom T; Gross M; Kluge B; Zhang SX; Doolen S
J Neurotrauma; 2006 Sep; 23(9):1366-78. PubMed ID: 16958588
[TBL] [Abstract][Full Text] [Related]
16. Targeting Rho to stimulate repair after spinal cord injury.
McKerracher L; Higuchi H
J Neurotrauma; 2006; 23(3-4):309-17. PubMed ID: 16629618
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases.
Ghittoni R; Patrussi L; Pirozzi K; Pellegrini M; Lazzerini PE; Capecchi PL; Pasini FL; Baldari CT
FASEB J; 2005 Apr; 19(6):605-7. PubMed ID: 15677697
[TBL] [Abstract][Full Text] [Related]
18. Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
Sarrabayrouse G; Pich C; Teiti I; Tilkin-Mariame AF
Int J Cancer; 2017 Feb; 140(4):747-755. PubMed ID: 27616679
[TBL] [Abstract][Full Text] [Related]
19. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257
[TBL] [Abstract][Full Text] [Related]
20. Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.
Sawada N; Liao JK
Antioxid Redox Signal; 2014 Mar; 20(8):1251-67. PubMed ID: 23919640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
